NCT03135509View on ClinicalTrials.gov

A Study to Assess the Relative Bioavailability of a New CC-220 Capsule Formulation, Compared to a Reference CC-220 Capsule Formulation, in Healthy Adult Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

May 24, 2017

Primary Completion Date

June 28, 2017

Study Completion Date

June 28, 2017

Conditions
Healthy Volunteers
Interventions
DRUG

CC-220

CC-220 gelatin capsules

Trial Locations (1)

66211

Quintiles Phase One Services, LLC, Overland Park

Sponsors

Lead Sponsor

Celgene
All Listed Sponsors
lead

Celgene

INDUSTRY

NCT03135509 - A Study to Assess the Relative Bioavailability of a New CC-220 Capsule Formulation, Compared to a Reference CC-220 Capsule Formulation, in Healthy Adult Subjects | Biotech Hunter | Biotech Hunter